Opthea Limited (OPT)
Market Cap | 695.22M |
Revenue (ttm) | 261,859 |
Net Income (ttm) | -220.24M |
Shares Out | 1.23B |
EPS (ttm) | -0.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,363 |
Open | 4.700 |
Previous Close | 4.600 |
Day's Range | 4.330 - 4.720 |
52-Week Range | 1.600 - 4.910 |
Beta | 1.61 |
Analysts | Strong Buy |
Price Target | 12.00 (+169.08%) |
Earnings Date | Aug 30, 2024 |
About OPT
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit V... [Read more]
Financial Performance
In 2024, Opthea's revenue was $261,859, a decrease of -32.03% compared to the previous year's $385,275. Losses were -$220.24 million, 54.5% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for OPT stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 202...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOU...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Reports Full-Year Financial Results and Business Updates
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for ...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1) will close at 5:00 pm (Melbourne ...
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
Financing extends Opthea's cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD
Opthea To Present at Clinical Trials at the Summit Meeting
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expecte...
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapi...
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leade...
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to tr...
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent...
Opthea Reports Half-Year Financial Results and Business Updates
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseas...